NASDAQ:AGEN

Agenus Stock Forecast, Price & News

$5.18
-0.01 (-0.19 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.12
$5.32
50-Day Range
$4.01
$5.64
52-Week Range
$2.50
$5.95
Volume1.56 million shs
Average Volume2.21 million shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
30 days | 90 days | 365 days | Advanced Chart
Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.


Agenus logo

About Agenus

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

747th out of 2,220 stocks

Biological Products, Except Diagnostic Industry

110th out of 213 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Agenus (NASDAQ:AGEN) Frequently Asked Questions

Is Agenus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus
or view top-rated stocks.

What stocks does MarketBeat like better than Agenus?

Wall Street analysts have given Agenus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Agenus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Agenus?

Agenus saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 22,580,000 shares, a drop of 13.1% from the June 30th total of 25,990,000 shares. Based on an average daily volume of 4,880,000 shares, the short-interest ratio is presently 4.6 days. Approximately 11.9% of the shares of the stock are short sold.
View Agenus' Short Interest
.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Agenus
.

How can I listen to Agenus' earnings call?

Agenus will be holding an earnings conference call on Monday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.04. The biotechnology company had revenue of $11.72 million for the quarter, compared to the consensus estimate of $21.81 million.
View Agenus' earnings history
.

How has Agenus' stock been impacted by Coronavirus (COVID-19)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGEN shares have increased by 90.4% and is now trading at $5.18.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AGEN?

3 brokers have issued 1-year price objectives for Agenus' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Agenus' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts' price targets for Agenus
or view top-rated stocks among Wall Street analysts.

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 68, Pay $1.07M)
  • Dr. Jennifer Buell, Pres & COO (Age 46, Pay $707.92k)
  • Ms. Christine M. Klaskin, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 55, Pay $362.97k)
  • Mr. Adam Krauss J.D., Chief Legal & Compliance Officer
  • Dr. Marc van Dijk Ph.D., Chief Technology Officer (Age 59)
  • Regina Grebla Ph.D., VP of Investor Relations & Communications
  • John Castle, Head of Translational Medicine & Bioinformatics
  • Mr. Paulo Moreira, Global Head of Clinical Operations
  • Mr. Dhan Chand, Scientific Director & Head of Drug Discovery
  • Mr. Alfred Dadson, Chief Manufacturing Officer

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Agenus' key competitors?

What other stocks do shareholders of Agenus own?

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.07%), Minot Wealth Management LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%), Cutler Group LP (0.00%) and Tuttle Tactical Management (0.01%).
View institutional ownership trends for Agenus
.

Which institutional investors are selling Agenus stock?

AGEN stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank .
View insider buying and selling activity for Agenus
or view top insider-selling stocks.

Which institutional investors are buying Agenus stock?

AGEN stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Cutler Group LP, Tuttle Tactical Management, and Minot Wealth Management LLC.
View insider buying and selling activity for Agenus
or or view top insider-buying stocks.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $5.18.

How much money does Agenus make?

Agenus has a market capitalization of $1.15 billion and generates $88.17 million in revenue each year. The biotechnology company earns $-180,910,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 359 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

Where are Agenus' headquarters?

Agenus is headquartered at 3 FORBES ROAD, LEXINGTON MA, 02421.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.